Johnson & Johnson may have incidentally scored a major victory in the Supreme Court case brought by another drugmaker, Bristol-Myers Squibb. Because of a Bristol ruling this summer, J&J has escaped a $72 million verdict in its ongoing talcum powder
read moreSurprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal. More: Bisaro steers Impax to .4B Amneal merger, creating fifth-largest U.S. generics company Source: fierce
read moreUnder a growing biosimilar assault, Johnson & Johnson’s big-selling immunology biologic Remicade held its ground again in the third quarter. Now, executives are planning their 2018 defense strategy for a critical medication that leads sales for the drug giant. More:
read moreIn the wake of Hurricane Maria, Johnson & Johnson executives say its Puerto Rico manufacturing facilities weathered the storm well and are getting back up to full speed, though some drug supplies could run short. More: Johnson & Johnson says
read moreSome drugmakers are responding to industrywide generics pricing pressure by bulking up via M&A. Not Novartis. The company plans to scale back or nix production of some generic drugs, and as a result, it’ll close a 450-employee Sandoz plant. More:
read moreA ‘no-deal’ Brexit that ends healthcare arrangements between the UK and the EU could end up costing the NHS as much as £500 million a year, warns a new paper published by the Brexit Healthcare Alliance, on the back of
read more© 1994 - 2026 B.M. Pharmaceuticals